Back to Search

Artesunate for Pulmonary Arterial Hypertension

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Recruiting Phase 1 Interventional Study
Pulmonary Arterial Hypertension (PAH)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 60
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
15 (estimated)
Sponsor
Joseph C. Wu · Other
Who this trial is looking for

This trial is looking for adults aged 18 to 75 years who have pulmonary arterial hypertension even though they are on other treatments. Participants will take artesunate daily for 20 weeks to see how safe it is.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 18 and 75 years old.
  • I have pulmonary arterial hypertension.
  • I am in WHO functional class I or II/III.
  • I have tried at least two other treatments.

You may not be able to join if

  • I have serious health problems as determined by my doctor.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria * Each participant must meet the following criteria to be enrolled in this study: * Adults aged 18 to 75 years. * WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimula…
Contacts

No contact information available.

NCT ID: NCT06872112 Source: ClinicalTrials.gov